
Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
- Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis
- Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent company
- Basel, as a global life sciences center, ideally located to attract top talent
Basel, June 1, 2023 — Sandoz AG, a global leader in generic and biosimilar medicines, has announced the location of its future permanent headquarters in central Basel.
The Sandoz AG headquarters plans to move to a landmark office building called “Elsässertor” in the center of Basel, right by the Basel SBB train station. Sandoz expects to move from the Novartis Campus to its new headquarters in mid-2024.
The announcement confirms the Sandoz commitment to Basel following its proposed separation from Novartis in the second half of 2023.
Sandoz CEO Richard Saynor says: “I’m delighted to confirm that we will continue to call Basel home. This is an important milestone on our way to becoming an independent company.
“Our planned location in the heart of the city will allow us to create a working environment that meets our business needs and reflects our identity, culture and values. Basel is a global center for the life sciences industry, attracting an unrivalled pool of talent and experience that will help us to grow further and achieve our ambition of being the sustainable global leader in generics and biosimilars.”
The planned new workspace will be designed to enable closer collaboration and teamwork across the organization. The move into the new office building will not impact the management of the Sandoz global business.
Sandoz Pharmaceuticals AG, the local Swiss affiliate, and Sandoz Group AG, the entity planned to be listed on the Swiss SIX stock exchange, remain based in Rotkreuz, Switzerland.
In August 2022, Novartis announced its intention to separate Sandoz, its off-patent medicines division, via a 100% spin-off. The proposed spin-off is due to complete in the second half of 2023 and would see Sandoz listed on the SIX Swiss exchange.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
# # #
About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.
Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandoz/global
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
# # #
Sandoz Global Communications | ||||||||
Central | North America | |||||||
Chris Lewis | +49 174 244 9501 | Leslie Pott | +1 609 627 5287 | |||||
Novartis Media Relations E-mail: media.relations@novartis.com | ||||||||
Central | North America | |||||||
Richard Jarvis | +41 79 584 2326 | Julie Masow | +1 862 579 8456 | |||||
Switzerland Satoshi Sugimoto | +41 79 619 2035 | |||||||
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com | ||||||||
Central | North America | |||||||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 345 4440 | |||||
Nicole Zinsli-Somm | +41 61 324 3809 | Parag Mahanti | +1 973 876 4912 | |||||
Isabella Zinck | +41 61 324 7188 |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Wolters Kluwer identifies ESG reporting challenges, demonstrates how technology brings clarity and competitive advantage25.9.2023 11:01:56 CEST | Press release
PRESS RELEASE Wolters Kluweridentifies ESG reporting challenges,demonstrates howtechnology brings clarity and competitive advantage Wolters Kluwer’s Corporate Performance and ESG divisionpoised to play leading role in enabling businesses to navigate emerging ESG reporting challenges LONDON – September 25, 2023– Wolters Kluwer’s Corporate Performance & ESG (CP & ESG) division has set out key issues major corporate and financial services institutions should consider when tackling emerging ESG reporting challenges. The insights are featured in a new white paper, “Bringing clarity to the complexity of financial and ESG reporting,” which zeroes in on the significant impact that the expected enforcement of global ESG regulations will have on multinational companies. The paper, authored by Wolters Kluwer CP & ESG experts, recommends that companies work quickly to leverage technology to bring clarity to the myriad of ESG expectations they face, by transforming the way they collect, report, ana
International Petroleum Corporation Announces Results of Normal Course Issuer Bid25.9.2023 11:00:00 CEST | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO)is pleased to announce that IPC repurchased a total of254,700IPC common shares (ISIN: CA46016U1084) during the period of September 18 to 22, 2023under IPC’s normal course issuer bid / share repurchase program (NCIB). IPC’s NCIB, announced on December 1, 2022, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/1052 (Safe Harbour Regulation) and the applicable rules and policies of the Toronto Stock Exchange (TSX) and Nasdaq Stockholm and applicable Canadian and Swedish securities laws. During the period of September 18 to 22, 2023, IPC repurchased a total of 210,000 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC. For more information regarding transactions under the NCIB in Sweden, including aggregated volume, weighted average pric
Festi hf.: Buyback program week 3825.9.2023 11:00:00 CEST | Press release
In week 38 2023, Festi purchased in total 130,000 own shares for total amount of 23,320,000 ISK as follows: WeekDateTimePurchased sharesShare pricePurchase price 38 19.sep 14:16:19 70.000 179,5 12.565.000 38 20.sep 13:55:36 30.000 179,5 5.385.000 38 21.sep 11:08:26 15.000 179 2.685.000 38 21.sep 14:53:42 15.000 179 2.685.000 130.00023.320.000 The execution of the buyback program is in accordance with the Act on Public Limited Companies No 2/1995, Article 5 of the Regulation of the European parliament and of the Council No. 596/2014, on market abuse, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase Festi held 9,275,668 own shares or 2.97% of issued shares. Festi has now bought in total 1,405,668 own shares for 265,982,037 ISK and holds today 9,405,668 own shares or 3.01% of issued shares. This announcement of purchase of own shares is in accordance with the buyback program announced 21 July 2023 to Nasdaq OMX
Share buy-back programme - week 3825.9.2023 10:30:44 CEST | Press release
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders Date 25.09.2023 Share buy-back programme - week 38 The share buy-back programme runs from and including 3 August 2023 up to and including 22 January 2024. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 385 million under a share buy-back programme, see company announcement of 2 August 2023. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme: DateNumber of sharesAverage purchase price (DKK)Total purchased under the programme (DKK)Total in accordance with the last announcement120,7001,010.12121,921,00318 September 20235,000989.804,949,00019 September 20234,500986.254,438,12520 September 20232,6001,004.722,612,27221 September 20234
Aktietilbagekøbsprogram - uge 3825.9.2023 10:30:44 CEST | pressemeddelelse
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter Dato 25.09.2023 Aktietilbagekøbsprogram - uge 38 Aktietilbagekøbsprogrammet løber i perioden fra og med den 3. august 2023 til og med den 22. januar 2024. I denne periode vil Ringkjøbing Landbobank tilbagekøbe aktier for en maksimal markedsværdi af 385 mio. kroner under et aktietilbagekøbsprogram, jf. selskabsmeddelelse af 2. august 2023. Programmet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016, der tilsammen udgør ”Safe Harbour”-reguleringen. Følgende transaktioner er foretaget under aktietilbagekøbsprogrammet: DatoAntal aktier (stk.)Gennemsnitlig købspris (kroner)Tilbagekøbt i alt underprogrammet (kroner)I alt i henhold til seneste meddelelse120.7001.010,12121.921.00318. september 20235.000989,804.949.00019. september 20234.500986,254.438.12520. september 20232.6001.004,722.612.27221. september 202